The growth of human breast tumor cells is regulated through signaling involving cell surface growth factor receptors and nuclear receptors of the steroid/thyroid/ retinoid receptor gene family. Retinoic acid receptors (RARs), members of the steroid/thyroid hormone receptor gene family, are ligand-dependent transcription factors, which have in vitro and in vivo growth inhibitory activity against breast cancer cells. RAR-agonists inhibit the proliferation of many human breast cancer cell lines, particularly those whose growth is stimulated by estradiol (E2) or growth factors. Additionally, RAR-agonists and synthetic retinoids such as Ferentinide have been shown to induce apoptosis in malignant breast cells but not normal breast cells. To better define the genes involved in RARmediated growth inhibition of breast cancer cells, we used oligonucleotide microarray analysis to create a database of genes that are potentially regulated by RAR-agonists in breast cancer cells. We found that PDCD4 (programmed cell death 4), a tumor suppressor gene presently being evaluated as a target for chemoprevention, was induced about three-fold by the RARa-selective agonist Am580, in T-47D breast cancer cells. RAR pan-agonists and Am580, but not retinoid X receptors (RXR)-agonists, stimulate the expression of PDCD4 in a wide variety of retinoidinhibited breast cancer cell lines. RAR-agonists did not induce PDCD4 expression in breast cancer cell lines, which were not growth inhibited by retinoids. We also observed that antiestrogen and the HER-2/neu antagonist, Herceptin (Trastuzumab), also induced PDCD4 expression in T-47D cells, suggesting that PDCD4 may play a central role in growth inhibition in breast cancer cells. Transient overexpression of PDCD4 in T-47D (ER þ , RAR þ ) and MDA-MB-231 (ER À , RAR À ) cells resulted in apoptotic death, suggesting a role for PDCD4 in mediating apoptosis in breast cancer cells. PDCD4 protein expression has previously been reported in small ductal epithelium of normal breast. To date, there has been no report of induction of PDCD4 expression by RAR-agonists, antiestrogen or HER2/neu antagonist in
Introduction
Breast cancer is the most common malignancy among women worldwide with over a million new cases being diagnosed annually (Bange et al., 2001) . Worldwide, breast cancer accounts for approximately 18% of all female cancers and in the US it represents 30% of all cancers diagnosed (Greenlee et al., 2000; McPherson et al., 2000; Bange et al., 2001) . It is a heterogeneous disease and despite recent advances in our understanding of the biology of the disease and the introduction of target selective therapy, the risk of relapse is still about 50% in newly diagnosed patient with localized disease and much higher in those with metastatic disease (Bange et al., 2001) . Thus, it is of utmost importance to identify and elucidate the various pathways that are involved in the growth control of these cells and to identify potential genes that could be targeted in the treatment of breast cancer.
Chemoprevention to prevent the progression of preneoplastic lesions is an important strategy in cancer therapy (Sun and Lotan, 2002) . Natural and synthetic derivatives of vitamin A (retinoids) are important mediators of cell growth and differentiation and have been studied as pharmacologic agents for preventing or treating cancer. all-Trans retinoic acid (ATRA), 9-cis retinoic acid (9-cRA) and 13-cis retinoic acid (13-cRA) are natural derivatives of vitamin A currently being used in treatment of cancer. Retinoids exert their biologic effects by binding to specific nuclear receptors expressed in target cells, the retinoic acid receptors (RARs: RARa, b, & g) (Mangelsdorf et al., 1995) , and the retinoid X receptors (RXRs: RXRa, b & g) (Mangelsdorf et al., 1992) . These receptors are ligand-dependent transcription factors that either induce or repress the transcription of target genes. The growth inhibitory effects of ATRA and other RAR-specific agonists on estrogen receptor positive (ER þ ) breast cancer cells have been well documented (Amos and Lotan, 1990; Seewaldt et al., 1995) . The antiproliferative effect of ATRA in breast cancer cell lines appears to result from a delay in the transition between the G0-G1 and S phase of the cell cycle (Seewaldt et al., 1997 (Seewaldt et al., , 1999 . Several key cell cycle regulatory genes such as Rb, cyclin D and E, cyclin dependent kinases 2, 4 and 6, and their inhibitors p15, p16, p21 and p27 have all been suggested as potential targets for retinoids in normal and malignant breast cells as well as other cell types that are sensitive to retinoid-mediated growth inhibition (Seewaldt et al., 1997 (Seewaldt et al., , 1999 Toma et al., 1997) . Recent studies also indicate that the apoptotic effects of retinoids in malignant breast cells is associated with downregulation of Bcl-2 and survivin and upregulation of antiapoptotic genes such as Bax and Bcl-2 and Bcl-xl (Raffo et al., 2000; Christine Pratt et al., 2003; Ye et al., 2004) . However, the basic mechanisms involved in the antiproliferative and apoptotic effects of RAR in malignant breast cells are poorly understood. Understanding these mechanisms will aid in the development of synthetic retinoids that can effectively treat and prevent cancer.
To identify and define the genes involved in RARmediated growth inhibitory effects on breast cancer cells, we used oligonucleotide microarray analysis to create a database of genes that are transcriptionally regulated by RAR-specific agonists in breast cancer cells. Preliminary analysis of this database shows that RAR-agonists induce the expression of several novel genes identified as tumor suppressor and apoptosis related genes.
In this study we show that RAR pan-agonists and the RARa-selective agonist, Am580, inhibit growth and rapidly stimulate the expression of PDCD4, a tumor suppressor gene, in the retinoid-responsive T-47D and MCF-7 breast cancer cell lines. PDCD4 (H731L) was originally isolated from a human glioma library by screening with an antibody against a nuclear antigen in proliferating cells . PDCD4 is homologous to the mouse gene Pdcd4 (also known as MA-3/TIS/A7-1) , which codes for a protein of 469 amino acid with a predicted size of 51.7 kDa (Cmarik et al., 1999) . The two human Pdcd4 homologs, H731L and H731, are, respectively, 96 and 93% identical to the mouse Pdcd4 gene (Yang et al., 2003a, b) . H731L and H731 are alternative transcripts of the same gene with H731 lacking 11 amino acids present within the N-terminus of mouse Pdcd4 and H731L (Yang et al., 2003a, b) . The human PDCD4 gene has been localized to chromosome 10q24 (Soejima et al., 1999) and its function is not well defined.
PDCD4 is ubiquitously expressed at low levels in normal tissues including normal breast epithelial cells, suggesting that it may play a role in normal breast physiology (Shibahara et al., 1995; Jurisicova et al., 1998; Yoshinaga et al., 1999) . Although PDCD4 expression has been documented in human breast cancer specimens, PDCD4 is far less frequently expressed in these specimens when compared to normal tissue . These data suggest that loss of PDCD4 expression may contribute to the development of breast cancer. In human lung cancer, loss of PDCD4 expression correlates with tumor progression and poor prognosis (Chen et al., 2003) . Murine Pdcd4 is known to inhibit the helicase activity of eukaryotic translation initiation factor 4A (eIF4A) (Yang et al., 2003a, b; Jansen et al., 2004) and has also been shown to suppress AP-1 expression in murine JB6 epidermal cells (Yang et al., 2001) . Very little is known about the upstream regulators and downstream targets of PDCD4 in normal cells. The physiologic role of PDCD4 in normal and malignant breast cells is unknown. In this study we present evidence for retinoid-regulated expression of PDCD4 in breast cancer cells and suggest a possible role for PDCD4 in apoptosis of breast cancer cells.
Results

RAR-agonists increase PDCD4 gene expression in T-47D and MCF-7 breast cancer cells
ATRA and other RAR-agonists such as Am580 inhibit estradiol-mediated growth stimulation of ER þ breast cancer cells (Afonja et al., 2002) . To identify retinoidregulated genes that may participate in growth inhibition and apoptosis, we performed microarray oligonucleotide analysis on T-47D cells breast cancer cells incubated with 50 nM Am580, a selective RARa-agonist at this concentration (Gianni et al., 1996; Afonja et al., 2002) . We opted to use a selective RARa-agonist for these studies because previous studies indicate that RARa expression in breast cancer cells correlates with retinoidmediated growth inhibition of breast cancer cells irrespective of their expression of the ER (Sheikh et al., 1994; Fitzgerald et al., 1997) . To identify early response genes that are critical for signaling via RARa, T-47D cells were incubated with Am580 over a time course ranging from 5 to 48 h. Initial analysis of the database for genes whose expression was increased two-to fivefold in Am580 treated T-47D breast cancer cells revealed induced levels of mRNA expression of several tumor suppressor genes and apoptosis related genes. One such gene was PDCD4, a tumor suppressor gene originally identified in human glioma cells. To confirm the data obtained in our microarray analysis, we obtained RNA from ATRA treated T-47D and MCF-7 breast cancer cells and performed a Northern blot analysis using a full-length PDCD4 labeled probe as described in Materials and methods. As shown in Figure  1a 
RAR-but not RXR-agonists increase PDCD4 protein expression in MCF-7 and T-47D cells
Breast cancer cells express several isoforms of RAR and RXR (Allenby et al., 1993; Fitzgerald et al., 1997) , which bind to their endogenous retinoid ligands with high affinity and specificity and thereby regulate discrete sets of target genes (Mangelsdorf, 1994; Fitzgerald et al., 1997) . To determine if induction of PDCD4 protein expression is mediated through RAR or RXR, T-47D and MCF-7 breast cancer cells were incubated with RAR-and RXR-specific agonists over a time course. Cells were cultured in the presence of 1 mM ATRA, 100 nM Am580 and 100 nM LGD 1069, an RXR-specific pan-agonist, for 2, 5, 24 and 48 h. Total cell lysate was isolated from these cells and analysed by immunoblotting using a specific PDCD4 polyclonal antibody (described in Materials and methods). We confirmed the specificity of this antibody by performing similar experiments with the polyclonal anti-H731 (anti-PDCD4) antibody used in studies published by Yoshinaga et al. (1999) . PDCD4 protein expression was induced by Am580 and ATRA in MCF-7 and T-47D cells as seen in Figure 2a and b. Only basal levels of expression of PDCD4 was observed when these cells were incubated with RXR-agonist (Figure 3 ), suggesting that induction of PDCD4 expression is mediated via RAR. Similar results were obtained in the ER þ ZR-75-1 cells (data not shown).
PDCD4 gene expression is induced in retinoid sensitive ER
À breast cancer cell lines
The growth-inhibitory effect of retinoids in breast cancer cells is thought to be mediated via RAR and this occurs primarily in breast cancer cells that express ER (Han et al., 1997) . Thus, we sought to determine if 
Antiestrogen and HER-2/neu antagonist induce PDCD4 expression
Published data suggest that some of the cellular effects of antiestrogens and the HER-2/neu antagonist, Herceptin, are mediated by RAR (Roman et al., 1993; Suzuki et al., 2001; Tari et al., 2002) . Thus, we sought to determine if antiestrogens and Herceptin induce PDCD4 expression in T-47D breast cancer cells, which express both the ER and HER-2/neu. PDCD4 protein expression was induced in T-47D cells within 5 h of incubation with 100 nM ICI-182780 (antiestrogen) or 2 mg/ml of Herceptin, similar to the results obtained with RAR agonists (Figure 5a and b) . PDCD4 protein expression appeared to be maximal by 5 h when T-47D cells were incubated with ICI-182780 and Herceptin. These findings suggest that PDCD4 may play a role in mediating growth inhibitory signals in breast cancer cells irrespective of the initiating event and secondly that the induction of PDCD4 expression in T-47D cells by Herceptin and antiestrogen may result from intracellular signaling crosstalk that exists between RAR, ER and HER-2/neu. We also analysed PDCD4 expression in T-47D cells treated with a combination of Herceptin and ATRA or ICI-182780 and ATRA. There was no clear indication that combination of these drugs resulted in a further increase in PDCD4 expression (data not included).
Induction of PDCD4 expression in SK-N-SH (neuroblastoma) and HL-60 (leukemia) cell lines
To further confirm RAR mediated induction of PDCD4 expression, we examined other human cancer cell lines that are known to be growth inhibited by RAR agonists. The SK-N-SH (neuroblastoma) and HL-60 (acute myeloid leukemia) cell lines are both known to undergo growth arrest and differentiation when incubated with ATRA (Lombet et al., 2001; Orlandi et al., 2003; Veselska et al., 2003) . We incubated these cells as well as Daoy medulloblastoma cells, with 1 mM ATRA for various times. Total cell lysate was obtained and analysed by immunoblotting with a PDCD4 specific antibody as previously described. PDCD4 expression was induced in both SK-N-SH and HL-60 cells both of which are growth inhibited by ATRA (Figure 6 ). Induction of PDCD4 expression was observed in Daoy medulloblastoma cells (data not shown), which are also growth inhibited by ATRA (Gumireddy et al., 2003) . HL-60, SK-N-SH and Daoy cells do not express ER or HER-2/neu indicating that PDCD4 expression can occur independent of these receptors.
Cell cycle changes in T-47D cells transiently expressing PDCD4
RAR agonists, antiestrogens, and Herceptin have been shown to induce a G0-G1 delay in breast cancer cells (Wilcken et al., 1997a, b; Mangiarotti et al., 1998; Le et al., 2003) . Since PDCD4 expression is increased in T-47D cells incubated with ATRA, antiestrogen and Herceptin, we asked if transient expression of PDCD4 in T-47D cells would induce cell cycle changes comparable to those observed when these cells are incubated with ATRA, antiestrogen and Herceptin. We engineered a green fluorescent protein (GFP)-PDCD4 expression vector, which allows us to use GFP as a marker for transfection and cell localization. GFP-PDCD4 localized primarily to the nucleus (Figure 7 ) of transfected T-47D and MDA-MB-231 cells although weak expression was also observed within the cytoplasm of transfected cells. Our findings are in agreement with published studies on expression of PDCD4 in breast cells and QT6 fibroblasts Bohm et al., 2003) . Nuclear localization was confirmed by DAPI staining (data not shown). Additionally, we detected the expression of endogenous PDCD4 only in nuclear extracts obtained from T-47D cells treated with 1 mM ATRA for 2 h (data not shown), 8 h (Figure 8) , and 24 h (data not shown). For cell cycle studies, cells were harvested 48 h after transfection and stained with propidium iodide (PI). Untransfected cells (GFP À ) ( Figure 9 , panel c) exhibited cell cycle parameters similar to untreated T-47D cells (Figure 9 , panel a) and showed a G0-G1 delay in the presence of 1 mM ATRA (not shown) as observed in T-47D cells treated with 1 mM ATRA (Figure 9, panel b) . In contrast, T-47D cells expressing GFP-PDCD4 (Figure 9 , panel d) did not exhibit a G0-G1 delay but rather had a significant increase in the number of cells in sub G0-G1 population, suggesting that these cells were undergoing cell death either by apoptosis or necrosis. These changes were not observed in cells exposed to the transfection reagent alone or in T-47D cells expressing GFP with a nuclear localizing sequence, which also localizes to the nucleus of the cell (data not shown). Incubation of transfected cells with 100 nM ICI-182780 and 1 mM ATRA did not induce cell cycle changes observed in untransfected cells treated with these ligands (data not . These results suggest that PDCD4 is not involved in G0-G1 phase arrest mediated by ATRA, antiestrogens and Herceptin but rather may play a role in cell death mediated by these agents.
Transient over-expression of PDCD4 induces apoptosis in T-47D and MCF-7 cells
To determine if cells were dying by apoptosis or necrosis, T-47D and MCF-7 cells were transfected with the GFP-PDCD4 vector and then subjected to TUNEL analysis using the TMR red cell death detection assay (Roche, USA). This assay allows for detection of DNA breaks (red fluorescence) in GFP-PDCD4 transfected cells (green fluorescence). Apoptosis was observed as early as 24 h and was maximal at 48 h following transfection ( Figure 10, panel a) . About 50% of transfected cell exhibited apoptosis by 24 h compared to a background apoptosis rate of o10% in untransfected cells and cells treated with only transfection reagent. The pan-caspase inhibitor zVAD-fmk, at 100 mM, inhibited apoptosis by 70-100% in GFP-PDCD4 expressing cells, suggesting that induction of apoptosis by PDCD4 is caspase dependent (Figure 10,  panel b ). To further demonstrate its role in apoptosis in breast cancer cells, we transfected GFP-PDCD4 into the MDA-MB-231 and MBA-MB-435 cells, two breast cancer cell lines that lack basal expression of PDCD4. When compared to cells incubated with transfection reagent alone, expression of PDCD4 induced apoptosis in both MDA-MB-231 and MDA-MB-435 breast cancer cells (data not shown). Additionally, transfection of wild-type (non-GFP) PDCD4 into MDA-MB-231 cells (Figure 11 ) and T-47D cells (not shown) was sufficient to induce apoptosis in these cells, thus confirming our findings with the GFP-PDCD4 construct.
Discussion
The focus of this study was to characterize the role of the tumor suppressor gene, PDCD4, in cellular responses mediated by the RAR in breast cancer cells. We identified PDCD4 as one of the genes whose expression was increased at least three-fold in T-47D cells incubated with Am580, an RARa-specific agonist. The present study demonstrates that RAR-agonists as well as antiestrogens and Herceptin induce the expression of PDCD4 in breast cancer cells that are growth inhibited by RAR-agonists. We observed basal levels of PDCD4 expression only in breast cancer cell lines that express RARa even in the absence of ER. Additionally, we show that PDCD4 expression is induced in other human tumors that express RARa but lack ER or HER-2/neu, suggesting that its induction in breast cancer cells occurs independent of the expression of these two receptors. Expression of the mouse Pdcd4 gene has been reported to be upregulated in response to apoptosis inducers and COX2 inhibitors (Onishi et al., 1998; Zhang and DuBois, 2001 ). Our study is the first report of induction of PDCD4 expression by RAR agonists. We speculate that the induction of PDCD4 expression by antiestrogen and Herceptin in breast cancer cells may result from intracellular crosstalk between RAR, ER and HER-2/ neu and that it may play an important role in the cellular responses mediated by these receptors in breast cancer cells. Several published findings support this hypothesis. Overexpression of HER-2/neu on malignant breast cells has been associated with retinoic acid resistance (Tari et al., 2002) . There is some suggestion that inhibition of HER-2/neu signaling results in upregulation of RAR signaling (Tari et al., 2002) . Additionally, it has been shown that selective HER-2/neu tyrophostins and RAR agonists cooperate to inhibit the growth of ovarian cells in -vitro, suggesting that HER-2/neu and RAR signaling interact in these cells (Grunt 2003; Offterdinger et al., 2003) . Both RAR and RXR agonists potentiate the action of 4-OH-tamoxifen to inhibit the growth of T-47D cells, suggesting that there is intracellular crosstalk among RAR, RXR and ER (Fitzgerald et al., 
PDCD4 induces apoptosis in breast cancer cells O Afonja et al 1997) . Thus, the incubation of RAR þ breast cancer cells with either antiestrogen or an HER-2/neu receptor antagonist might result in the expression of a group of genes that are also regulated via RARs and PDCD4 may be one such gene.
Our findings of basal expression of PDCD4 in breast cancer cell lines that represent less aggressive phenotypes suggest that PDCD4 may play a role in normal breast physiology. PDCD4 has been reported to be ubiquitously expressed at low levels in normal tissues including normal breast (Azzoni et al., 1998; Jurisicova et al., 1998; Yoshinaga et al., 1999) . Its expression has been documented in human breast cancer specimens. However, its frequency of expression appears to be decreased when compared with normal breast samples. Interestingly, breast cancer tissues that express PDCD4 protein showed increased amount of the protein compared to normal tissues, suggesting that accumulation of PDCD4 may be an antiproliferative response induced in the malignant breast cells (Shibahara et al., 1995) . It has been suggested that low levels of functional PDCD4 may be essential for cell proliferation and accumulation of the protein in the nucleus may negatively regulate cell proliferation (Shibahara et al., 1995) . Our observation of the lack of basal expression of PDCD4 in most of the ER À breast cancer cell lines that we analysed suggests that loss of PDCD4 expression may contribute to the development of aggressive malignant breast cancer. Jansen et al. (2003 Jansen et al. ( , 2004 have recently analysed the NCI panel of 60 human tumor cell lines for PDCD4 expression and chemosensitivity and found that expression of PDCD4 in breast cancer cell lines correlated with increased sensitivity to Tamoxifen. Interestingly, they documented relatively high PDCD4 expression in MDA-MB-435 cells but not in MDA-MB-231 cells (Jansen et al., 2004) . Our results are different and it is possible that the findings we observe are unique to the cells analysed in our study. Additionally, the discrepancy in our result may be due to the sensitivity of the antibody used in our studies.
PDCD4 is considered to be a tumor suppression gene. The mechanism(s) by which PDCD4 inhibits tumor growth has not been fully elucidated. It has been suggested that PDCD4 may function as a tumor suppressor gene by interacting with the eukaryotic initiation factor, eIF4A, and inhibiting translation. This also suggests that PDCD4 may inhibit expression of key proteins that regulate cell death and proliferation. It has been previously observed that PDCD4 protein expression increases during the G0-G1 phase of cell cycle and decreases in S phase in proliferating cells (Matsuhashi et al., 1987 . However, our studies suggest that the changes in PDCD4 expression during the cell cycle do not mediate the observed cell cycle changes. Thus, we did not observe any change in the percentage of cells in different phases of the cell cycle in T-47D cells expressing GFP-PDCD4. We did however observe an increase in the sub G0-G1 population in T-47D cells expressing GFP-PDCD4, indicating that PDCD4 may play a role in apoptosis of breast cancer cells and is not involved in cell cycle regulation of these cells. PDCD4 was originally identified as an apoptosis-related gene in a glioma cDNA library. In this study we show that overexpression of PDCD4 in breast cancer cells is sufficient to induce apoptosis in these cells and this occurs via a caspase dependent mechanism. Several in vitro and in vivo studies indicate that retinoids induce apoptosis in malignant breast cells but not in normal mammary epithelial cells (Dietze et al., 2002) , and that ATRA-induced apoptosis in breast cancer cells involves the mitochondrial pathway (Niu et al., 2001) . However, the genes that are critical for this process have not been fully elucidated. Since transient expression of PDCD4 induces apoptosis in both ER þ and ER À breast cancer cells, we speculate that PDCD4 may be one of the genes involved in RAR-mediated apoptosis in breast cancer cells.
A question to be addressed in future studies is the role of PDCD4 in RAR-mediated apoptosis. PDCD4 has been shown to inhibit transactivation of AP-1 in JB6 epidermal cells (Yang et al., 2001 (Yang et al., , 2003a . RARagonists downregulate AP-1 expression in breast cancer cells and this is believed to contribute to the cellular phenotype induced by retinoids in breast cancer cells (Salbert et al., 1993; Fanjul et al., 1994) . It is possible that PDCD4 is involved in retinoid-mediated downregulation of AP-1 in breast cancer cells and this may also be involved in the apoptosis phenotype observed in T-47D that overexpress PDCD4. Whether PDCD4 influences the activity of AP-1 in breast cancer cells needs further exploration.
In summary, our results indicate that PDCD4 expression is induced in retinoid-sensitive breast cancer cell lines as well as in retinoid-sensitive neuroblastoma and myeloid leukemia cells. In addition, induction of PDCD4 by antiestrogen and Herceptin suggests that it may play a role in growth inhibitory signaling that are mediated via RAR, ER and the HER-2/neu receptor. Our findings also support a role for PDCD4 in caspasedependent apoptosis in RAR-agonist responsive breast cancer cell lines. In future studies, we hope to identify the primary target genes regulated by PDCD4 in breast cancer cells and to define their role in mediating effects on the growth and biological behavior of breast cancer cells both in culture and in vivo.
Materials and methods
Cell lines
MCF-7, T-47D, ZR-75-1, SK-BR-3, MDA-MB-435, MDA-MB-231 and BT-20 breast cancer cell lines were obtained from American Type Tissue Culture Collection (ATCC; Rockville, MD, USA) and were maintained in DMEM (Mediatech Inc., USA) supplemented with 10% fetal calf serum (FCS). Daoy (medulloblastoma), SK-N-SH (neuroblastoma) and HL-60 (myeloid leukemia) cell lines were also obtained from the ATCC. Daoy and SK-N-SH cells were maintained in MEM (Eagles) (Mediatech Inc., USA) supplemented with 0.1 mM nonessential amino acids, 1.0 mM sodium pyruvate and 10% FCS. HL-60 cells were maintained in RPMI 1640 (Mediatech Inc., USA) supplemented with 10% FCS.
Ligands all-Trans retinoic acid (ATRA) and LGD-1069 were obtained from Sigma and Ligand pharmaceuticals respectively. Am580 was obtained from the Faculty of Pharmaceutical Sciences, University of Tokyo, Japan (Kagechika et al., 1988) . Herceptin was obtained as a kind gift from Dr Franco Muggia (NYU School of Medicine, NY, NY). ICI-182780 was obtained from AstraZeneca. Cells were incubated with either 1 mM ATRA, 50 nM Am580, 100 nM LGD-1069, 100 nM ICI-182780 or 2 mg/ ml Herceptin for 2-48 h. Control cells were incubated with either DMSO or ethanol.
Northern blotting
MCF-7 and T-47D cells were cultured as monolayers in 75 cm 2 tissue culture flasks containing DMEM supplemented with 10% FCS. Cells were exposed to receptor ligands, at concentrations previously mentioned, for 2, 5, 24 or 48 h. Total cell RNA was prepared using the acid guanidium thiocyanatephenol-chloroform method (Chomczynski and Sacchi, 1987) . In all, 25 mg of total RNA was electrophoresed in 0.8% agarose gels containing 0.66 M formaldehyde and transferred onto nylon membrane (Osmonics, Westborough, MA, USA) by electroblotting. The membranes were incubated at 681C for 1 h with prehybridization buffer (Amersham Pharmacia Biotech, USA) containing 0.125 mg/ml of salmon sperm DNA and 0.5X SSC. A 1.5 kb full-length PDCD4 cDNA was used as a probe (see section on RT-PCR and plasmids) and labeled with a-32 P-dCTP (NEN Life science Products, Boston, MA, USA) using Rediprime random priming labeling reagents (Amersham Pharmacia Biotech, USA). Hybridization was at 681C for 18 h in hybridization buffer containing 1 Â 10 6 dpm/ml of labeled probe. After washing with 2 Â SSC/0.5% SDS for 20 min at room temperature and in 0.2 Â SSC/0.5% SDS for 20 min at 651C, the membranes were exposed to a phosphoimager overnight and the signal obtained quantitiated using phosphoimager Storm A20 software (Molecular Dynamics, Amersham Pharmacia Biotech, USA).
Western blotting
Cells were plated in six-well tissue culture plates at a density of 0.2 Â 10 6 cells/well in 5 ml of 10% FCS supplemented DMEM medium containing either DMSO (vehicle used to dissolve various retinoid compounds), Herceptin, ICI-182780 or the retinoid receptor ligands at concentrations previously mentioned. Following incubation for a given time period, the medium was removed and the cells were washed twice with PBS. Whole-cell extracts were prepared by suspending the cells in lysis buffer (60 mM Tris (pH 7.5), 7.5% glycerol, 5% 2-mercaptoethanol and 1% SDS), and the protein concentration determined using the BCA assay (Bio-Rad Laboratories, Hercules, CA, USA). Extracts containing 25 mg of protein were electrophoresed in 10% polyacrylamide-SDS denaturing gels and transferred onto nitrocellulose membrane (Osmonics, Westborough, MA, USA) over 4 h by electroblotting. Ponceau S staining of the membrane and Coomassie blue staining of the SDS-PAGE gel were used to confirm that equal amounts of protein were transferred from each lane. The membrane was blocked with 5% nonfat milk in TBS (50 mM Tris (pH 7.5) and 150 mM NaCl). The membrane was then incubated with rabbit polyclonal PDCD4 antibody at a 1 : 1000 dilution overnight at 41C. After washing with TBS, the membrane was incubated with goat anti-rabbit IgG conjugated with horseradish peroxidase (1 : 2000 dilution) for 1.5 h at room temperature. The membrane was then washed with TBS twice followed by two washes with TBS containing 0.05% Tween 20 and developed using enhanced chemiluminescence (ECL) (Pierce, USA). Membranes were subsequently stripped using stripping buffer (0.1 M glycine, pH 2.4) and incubated with b-actin antibody (Santa Cruz, USA) at a 1 : 1000 dilution overnight at 41C, washed with TBS, incubated with goat anti-rabbit IgG conjugated with horseradish peroxidase as previously described and developed using ECL.
Preparation of Anti-PDCD4 antibody The anti-PDCD4 antibody was prepared by immunizing a rabbit with KLHconjugated peptide corresponding to the 15 amino-acid sequences in the amino-terminal of protein. PDCD4 plasmid was transfected into NIH3T3 cells and cell extracts from transfected and untransfected cells was used to determine the specificity of the antibody. A single band was seen on Western blot analysis and was compared to results obtained with the anti-H731 (anti-PDCD4) antibody used in studies published by Yoshinaga et al. (1999) .
Preparation of nuclear and cytoplasmic extracts
T-47D cells were cultured as monolayer in 60-mm tissue culture dish containing DMEM supplemented with 10% FCS and incubated with either DMSO or 1 mM ATRA for 2-24 h. Cells were washed in culture dishes with ice-cold 1 Â phosphate-buffered saline (PBS) three times and then harvested into 1.5 ml microcentrifuge tubes using cell scraper. Cells were then pelleted at 1500 r.p.m. for 5 min and resuspended in 400 ml of freshly prepared buffer A (10 mM HEPES (pH 7.8), 10 mM KCl, 1 mM EDTA (pH 8.0) and 1 Â protease inhibitor cocktail (Roche, USA)). The mixture was vortexed vigorously for 2 min and then centrifuged for 1 min at 7000 r.p.m. to obtain the cytoplasmic fraction. In total, 4 M KCl and glycerol were added to cytoplasmic extract to achieve a final concentration of 10 mM KCl and 2% glycerol, respectively. The nuclear pellet was resuspended in 100 ml buffer C (50 mM HEPES, 420 mM KCl, 0.1 mM EDTA (pH 8.0), 5 mM MgCl 2 , 2% glycerol and 1 Â protease inhibitor cocktail (Roche, USA), vortexed vigorously for 1 min and then incubated on ice for 30 min. The mixture was then centrifuged at 13 000 r.p.m. for 15 min and supernatant (nuclear extract) was collected into a clean 1.5 ml microcentrifuge tube. Protein concentration was determined using the BCA assay (Bio-Rad Laboratories, Hercules, CA, USA).
RT-PCR and plasmids
RT-PCR was carried out using standard procedures. In all, 1 mg of total RNA obtained from ATRA treated T-47D breast cancer cells was subjected to reverse transcription using oligodT as the primer, and PDCD4 cDNA was amplified by PCR. Full-length PDCD4 was amplified using the following primers 5 0 CCGGGATCCACCATGGATGTAGAAAATGAGCAGAT AC 3 0 (sense) (genebank accession number XM_005698, nucleotide 85-109, highlighted in bold font in primer sequence) and 5 0 CCCTCGAGGTACCTCAGTAGCTCTCTGGTTTA AGACGACC 3 0 (antisense) (genebank accession number XM_005698, nucleotide 1494-1468, highlighted in bold font in primer sequence), which contain unique restriction enzyme sites to allow for cloning into a pEGFP-C1 vector (Clontech, USA). PCR conditions were 941C for 2 min and 30 cycles of denaturation at 941C for 1.5 min, annealing at 601C for 1.5 min and extension at 721C for 1.5 min. A 1.5-kb, full-length PDCD4 PCR product was amplified and was subsequently sequenced to confirm integrity of the amplified product. Full-length PDCD4 cDNA was cloned, in frame, into the BglII-KpnI site of pEGFP-C1 (Clontech, USA). Sequencing of isolated plasmid DNA confirmed orientation and integrity of the cloned fragment. The full-length cDNA obtained was also used as a probe for Northern blotting.
Transient transfection
Cell cycle analysis T-47D cells were plated at a density of 0.2 Â 10 6 cells/well in six-well tissue culture plates. The cells were transfected with 2.5-5 mg of GFP-PDCD4 using Genefect transfection reagent (Mediatech Inc., USA). Briefly, cells were transfected with plasmid DNA in 0.8 ml serum-free medium for approximately 5 h, following which 1 ml of medium containing 20% FCS was added and left to incubate overnight. Fresh medium containing 10% FCS was added the following day. Cells were harvested 48 h later using trypsin-EDTA for about 2 min and then centrifuged at 1500 r.p.m. for 5 min.
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Following two washes with PBS, the cells were fixed with ice-cold 70% ethanol and left at À201C overnight. Cells were then centrifuged and washed once with PBS. For cell cycle analysis, the ethanol-fixed cells were re-suspended in staining solution (50 mg/ml PI and 100 mg/ml RNase A in PBS). Samples were stored at 41C in the dark for at least 1 h prior to analysis. Flow cytometric analysis for GFP and PI was performed using a four-color FACScan (Becton-Dickson Immunocytometry Systems, San Jose, CA, USA). GFPpositive cells were analysed for cell cycle changes. GFPnegative cells in the same transfection were also analysed for cell cycle changes and served as an internal control for each experiment.
TUNEL assay T-47D, MCF-7, MDA-MB-231 and MDA-MB-435 breast cancer cells were plated at a density of 3 Â 10 4 cells/well on coverslips in 24-well tissue cultures plates. The cells were then transfected with GFP-PDCD4 or wild-type PDCD4 (non-GFP) using Lipofectamine 2000 transfection reagent (Invitrogen, USA), according to the manufacturer's protocol. The cells were transfected with 500 ng of plasmid DNA in 500 ml of Opti-MEM serum-free medium (Invitrogen, USA). At 6 h after transfection, medium was aspirated, replaced with complete growth medium containing either DMSO (control) or 50-100 mM zVAD-fmk (pan-caspase inhibitor) and cells were left to incubate overnight. Analysis for apoptosis was carried out using the TMR red In situ Cell Death Detection kit (Roche, USA), according to the manufacturer's guidelines. Briefly, breast cancer cells, plated on coverslips in 24-well plates, were washed thrice with 1 Â PBS and then fixed with freshly prepared paraformaldehyde (4% in PBS, pH 7.4) for 1 h at room temperature. After washing twice with 1 Â PBS, these cells were then permeabilized on ice for 2 min with 0.1% Triton X-100 in 0.1% sodium citrate. Permeabilization solution was removed and after two rinses in PBS, the fixed and permeablized cells were then incubated with the TUNEL reaction mix containing TMR red tagged dUTP and terminal deoxynucleotidyl transferase (TdT). This allows for detection of apoptosis as red fluorescence. Labeling was carried out for 1 h at 371C. Cells were rinsed twice with PBS and then stained with 1 : 4000 dilution of a 2 mg/ml stock solution Hoechst No. 33258 (DAPI) (Sigma, USA) according to manufacturer's guidelines. Coverslips were subsequently mounted onto slides and analysed using a Zeiss fluorescence microscope.
